PND37 The Cost-Effectiveness of Buccolam® (Licensed Oromucosal Midazolam) for the Treatment of Acute Epileptic Seizures in the UK; a Hybrid Model Solution
Abstract
Authors
D. Lee A. Batty D. Gladwell N.J. Brereton E. Tate
D. Lee A. Batty D. Gladwell N.J. Brereton E. Tate
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now